Innate Pharma SA (0EVI) Financial Statements
Innate Pharma SA Financial Overview
Innate Pharma SA's market cap is currently $140.30M. The company's EPS TTM is $-0.51; its P/E ratio is -2.46; Innate Pharma SA is estimated to report earnings on March 25, 2027, and the estimated EPS forecast is $-0.25. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.79M | $ 12.62M | $ 51.90M | $ 49.64M | $ 12.11M |
| Gross Profit | $ 2.79M | $ -31.86M | $ 5.62M | $ 6.01M | $ -34.89M |
| Operating Income | $ -57.36M | $ -51.58M | $ -12.67M | $ -24.63M | $ -47.83M |
| EBITDA | $ -55.97M | $ -50.99M | $ -1.84M | $ -61.30M | $ -43.23M |
| Net Income | $ -49.18M | $ -49.47M | $ -7.57M | $ -58.10M | $ -52.81M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 34.31M | $ 80.77M | $ 92.46M | $ 101.48M | $ 119.84M |
| Total Assets | $ 62.72M | $ 111.06M | $ 184.19M | $ 207.86M | $ 267.50M |
| Total Debt | $ 22.57M | $ 31.37M | $ 39.89M | $ 42.25M | $ 44.25M |
| Net Debt | $ -5.52M | $ -35.03M | $ -30.71M | $ -41.97M | $ -59.51M |
| Total Liabilities | $ 84.42M | $ 102.22M | $ 132.29M | $ 153.71M | $ 160.06M |
| Stockholders' Equity | $ -21.70M | $ 8.83M | $ 51.90M | $ 54.15M | $ 107.44M |
| Cash Flow | |||||
| Free Cash Flow | $ -52.90M | $ -7.29M | $ -34.91M | $ -20.28M | $ -59.79M |
| Operating Cash Flow | $ -52.76M | $ -6.90M | $ -32.56M | $ -19.15M | $ -58.46M |
| Investing Cash Flow | $ 7.29M | $ 9.20M | $ 20.63M | $ 1.88M | $ -917.00K |
| Financing Cash Flow | $ 6.07M | $ -6.01M | $ -1.97M | $ -1.83M | $ 26.82M |
Currency in EUR
